Agenus Inc.   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Lexington MA United States (1994)

Organization Overview

First Clinical Trial
2000
NCT00081809
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

AgenTus Therapeutics, Inc. | Agenus Inc.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Lung Injury (Phase 1)

Carcinoma (Phase 3)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Carcinoma, Renal Cell (Phase 3)

Central Nervous System Neoplasms (Phase 2)

Glioblastoma (Phase 2)

Gliosarcoma (Phase 2)

Hemangiosarcoma (Phase 2)

Herpes Genitalis (Phase 2)

Herpes Simplex (Phase 2)

Kidney Neoplasms (Phase 3)

Leukemia (Phase 2)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive (Phase 2)

Leukemia, Myeloid (Phase 2)

Lung Neoplasms (Phase 2)

Lymphoma (Phase 2)

Lymphoma, B-Cell (Phase 1)

Lymphoma, Follicular (Phase 2)

Melanoma (Phase 3)

Neoplasms (Phase 1)

Nervous System Neoplasms (Phase 2)

Recurrence (Phase 2)

Respiratory Distress Syndrome (Phase 1)

Respiratory Distress Syndrome, Newborn (Phase 1)

Sarcoma (Phase 2)

Syndrome (Phase 1)

Uterine Cervical Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 55
  • # of Trial APIs: 43